Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Kali Phosphoricum
Brand Name
Jacksons Cell Salts Kali Phos 6x
Generic Name
Kali Phosphoricum
Active Ingredient
Potassium Phosphate, DibasicCategory
Non-Standardized Plant Allergenic Extract [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 6 [hp_X]/6[hp_X] | PELLET | ORAL | 84739-007 |
Detailed information about Jacksons Cell Salts Kali Phos 6x
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Jacksons Cell Salts Kali Phos 6x, you must consult a qualified healthcare professional.
Potassium Phosphate, Dibasic is a vital mineral supplement and buffering agent used to treat hypophosphatemia and regulate urinary acidity. It belongs to the class of electrolyte replenishers.
Dosage of Potassium Phosphate, Dibasic must be highly individualized based on the patient's serum electrolyte levels, renal function, and the severity of the deficiency. For the treatment of mild to moderate hypophosphatemia, oral doses typically range from 10 to 15 mmol of phosphorus taken 2 to 3 times daily. In acute, severe cases requiring intravenous intervention, healthcare providers may prescribe 0.08 to 0.64 mmol/kg of phosphate infused over 4 to 12 hours. For urinary acidification, doses of 1 gram (approximately 7.4 mmol of phosphorus) four times daily after meals and at bedtime are common. It is vital to note that 'mmol' refers to the phosphate content, while 'mEq' refers to the potassium content; clinicians must distinguish between these units to avoid dosing errors.
In pediatric patients, Potassium Phosphate, Dibasic is primarily used to treat or prevent rickets and to support growth in infants receiving parenteral nutrition. For infants, a typical maintenance dose in TPN is 0.5 to 1.5 mmol/kg/day. For older children, oral supplementation for phosphate-losing conditions may range from 15 to 40 mg/kg/day of elemental phosphorus, divided into multiple doses. Pediatric dosing requires extreme caution due to the higher risk of developing hyperkalemia (high potassium) or hypocalcemia (low calcium) in smaller bodies. This medication is not recommended for children without direct supervision by a pediatric endocrinologist or nephrologist.
Patients with renal impairment (decreased kidney function) are at the highest risk for toxicity. If the Glomerular Filtration Rate (GFR) is less than 30 mL/min, the dose should be reduced by at least 50%, and serum levels must be monitored daily. In cases of end-stage renal disease (ESRD), Potassium Phosphate, Dibasic is generally contraindicated unless the patient has a documented, symptomatic deficiency that cannot be managed otherwise.
No specific dosage adjustments are typically required for hepatic (liver) impairment, as the liver does not play a primary role in the clearance of potassium or phosphate. However, patients with liver failure often have secondary renal issues (hepatorenal syndrome), which would necessitate cautious dosing.
Geriatric patients often have undiagnosed reductions in renal clearance. Healthcare providers usually start at the lower end of the dosing range and monitor cardiac and renal function closely. The risk of potassium-induced arrhythmias is significantly higher in this population.
When taking oral forms of Potassium Phosphate, Dibasic, it is generally recommended to take the medication with a full glass of water after meals to minimize gastrointestinal irritation. If using a powder form, ensure it is completely dissolved in at least 4 ounces of water or juice before consumption. For intravenous forms, NEVER administer the medication as a rapid 'bolus' or undiluted injection. It must be diluted in a compatible large-volume parenteral fluid (like 0.9% Sodium Chloride or 5% Dextrose) and infused slowly via a pump to prevent cardiac arrest. Store all forms at room temperature ($20^{\circ}C$ to $25^{\circ}C$ or $68^{\circ}F$ to $77^{\circ}F$), away from moisture and direct light.
If you miss a dose of the oral supplement, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to 'catch up,' as this can lead to a sudden spike in potassium or phosphate levels, which may be dangerous.
Signs of an overdose of Potassium Phosphate, Dibasic are primarily those of hyperkalemia and hyperphosphatemia. Symptoms include muscle weakness, tingling in the hands or feet (paresthesia), confusion, a heavy feeling in the legs, and a slow or irregular heartbeat. In severe cases, this can lead to cardiac arrest or tetany (muscle spasms) due to secondary hypocalcemia. If an overdose is suspected, seek emergency medical attention immediately. Treatment typically involves the administration of calcium gluconate to stabilize the heart, insulin/glucose to shift potassium into cells, and potentially hemodialysis to remove excess ions from the blood.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as electrolyte shifts can have profound effects on heart rhythm.
The most frequently reported side effects of Potassium Phosphate, Dibasic, particularly with oral administration, involve the gastrointestinal tract. Because phosphate salts have an osmotic effect (drawing water into the intestines), many patients experience diarrhea or loose stools. This is often dose-dependent and may resolve as the body adjusts to the medication. Other common effects include:
As the body processes the increased mineral load, some patients may notice:
Rarely, patients may experience more systemic reactions, including:
> Warning: Stop taking Potassium Phosphate, Dibasic and call your doctor immediately if you experience any of these serious symptoms. These may indicate a life-threatening electrolyte imbalance.
Prolonged use of Potassium Phosphate, Dibasic can lead to several chronic complications:
No FDA black box warnings are currently issued specifically for Potassium Phosphate, Dibasic. However, the FDA does require prominent warnings on the labels of concentrated potassium injections regarding the risk of fatal cardiac arrest if administered undiluted. Healthcare providers are strictly cautioned to verify the dilution and infusion rate before administration.
Report any unusual symptoms to your healthcare provider. Monitoring of blood levels is the only way to ensure these side effects are caught before they become dangerous.
Potassium Phosphate, Dibasic is a high-alert medication when administered intravenously. The most critical safety concern is the prevention of hyperkalemia and hyperphosphatemia. Patients must be aware that this medication is not a simple 'vitamin' but a potent electrolyte that directly influences heart rhythm and nerve function. It should only be used when laboratory monitoring is readily available. Patients with pre-existing heart disease, kidney disease, or those taking certain blood pressure medications must exercise extreme caution.
No FDA black box warnings for Potassium Phosphate, Dibasic. However, the American Society for Health-System Pharmacists (ASHP) and the FDA emphasize that concentrated potassium solutions are among the most common causes of medication errors leading to death in hospital settings. These products must be stored separately from other IV fluids to prevent accidental undiluted administration.
Patients receiving Potassium Phosphate, Dibasic require regular laboratory testing to ensure safety:
Potassium Phosphate, Dibasic generally does not cause sedation. However, if a patient experiences dizziness, confusion, or muscle weakness due to electrolyte shifts, they should avoid driving or operating heavy machinery until their levels have stabilized and they have been cleared by a physician.
Alcohol consumption should be limited while taking this medication. Chronic alcohol use is a common cause of hypophosphatemia, but acute alcohol ingestion can interfere with electrolyte balance and increase the risk of gastrointestinal irritation or dehydration, which complicates phosphate therapy.
Abruptly stopping Potassium Phosphate, Dibasic in a patient with chronic depletion can lead to a return of symptoms like muscle weakness and bone pain. However, there is no 'withdrawal syndrome' in the traditional sense. If the medication is being used to treat an acute deficiency, it is typically tapered off as the patient's oral intake improves and laboratory values normalize.
> Important: Discuss all your medical conditions, especially heart or kidney problems, with your healthcare provider before starting Potassium Phosphate, Dibasic.
Certain medications should never be used in conjunction with Potassium Phosphate, Dibasic due to the extreme risk of life-threatening hyperkalemia:
Potassium Phosphate, Dibasic can directly affect several laboratory results:
For each major interaction, the primary management strategy is frequent laboratory monitoring and dose titration. If a patient must take an ACE inhibitor, the healthcare provider may choose a lower dose of Potassium Phosphate or switch to a sodium-based phosphate supplement if the patient's sodium levels allow.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as many 'hidden' sources of potassium exist in over-the-counter products.
Potassium Phosphate, Dibasic must NEVER be used in the following conditions:
Conditions requiring a careful risk-benefit analysis include:
There is no known cross-sensitivity between Potassium Phosphate, Dibasic and unrelated drug classes. However, patients who have had allergic reactions to other phosphate salts (like Sodium Phosphate) or potassium salts (like Potassium Chloride) should be monitored for similar hypersensitivity reactions. The inactive ingredients in tablets or the preservatives in multi-dose vials may also be a source of sensitivity.
> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and current heart health, before prescribing Potassium Phosphate, Dibasic.
Potassium Phosphate, Dibasic is generally classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether it can cause fetal harm when administered to a pregnant woman. However, phosphorus and potassium are normal constituents of the human diet and are essential for fetal development. In pregnant women with severe hypophosphatemia, the benefits of treatment usually outweigh the theoretical risks. It is crucial to maintain normal mineral levels to prevent maternal complications like osteomalacia (softening of the bones) and fetal growth restriction. Use in pregnancy should be strictly supervised by an obstetrician and a specialist in metabolic medicine.
Both potassium and phosphate are naturally excreted in human breast milk. When used at physiological doses to correct a deficiency, Potassium Phosphate, Dibasic is generally considered compatible with breastfeeding. There are no documented reports of adverse effects on nursing infants when the mother's serum levels are maintained within the normal range. However, high doses that lead to maternal hyperphosphatemia could theoretically alter the mineral composition of the milk. Monitoring the infant for signs of GI upset or irritability is recommended if the mother is on high-dose therapy.
As previously discussed, this medication is used in children primarily for the treatment of rickets and in neonatal TPN. Children have higher phosphate requirements per kilogram of body weight than adults due to active bone growth. However, their renal systems are less mature, particularly in neonates, making them more susceptible to toxicity. Growth parameters and bone age should be monitored in children on long-term phosphate therapy. It is NOT approved for use in children for 'general health' or without a specific medical diagnosis of deficiency.
Elderly patients are at a significantly increased risk for adverse effects. Age-related declines in GFR mean that potassium and phosphate are cleared more slowly. Furthermore, the elderly are more likely to be taking 'polypharmacy' (multiple medications), including diuretics and blood pressure drugs that interact with potassium. There is also a higher risk of 'orthostatic hypotension' (dizziness when standing), which can be exacerbated by electrolyte shifts, leading to falls and fractures. Clinical monitoring should be more frequent in this age group.
Renal impairment is the most significant contraindication and precaution for this drug. In patients with a GFR of 30-60 mL/min, doses must be reduced and monitored. In those with a GFR below 30 mL/min, the risk of 'metastatic calcification' (calcium deposits in organs) is extremely high. Dialysis patients may require phosphate binders rather than supplements, as they typically struggle with high phosphate levels.
While the liver does not clear this drug, hepatic patients often have complex fluid and electrolyte issues, such as ascites (fluid in the abdomen). Potassium levels must be monitored closely in patients with cirrhosis, as they are often on high-dose diuretics like Spironolactone, which contraindicates the use of Potassium Phosphate.
> Important: Special populations require individualized medical assessment and frequent blood work to ensure safety.
Potassium Phosphate, Dibasic acts as an exogenous source of the phosphate ($HPO_4^{2-}$) and potassium ($K^+$) ions. The phosphate ion is essential for the formation of high-energy phosphate bonds in ATP and creatine phosphate. It also serves as a structural component of phospholipids in cell membranes and nucleotides in DNA and RNA. In the skeletal system, it combines with calcium to form hydroxyapatite, the primary mineral of the bone matrix. In the renal tubules, the dibasic phosphate ion acts as a buffer, accepting a hydrogen ion to become monobasic phosphate ($H_2PO_4^-$), which allows for the excretion of acid while maintaining systemic pH. The potassium ion maintains the electrical excitability of nerves and muscles by regulating the resting membrane potential through the $Na^+/K^+$-ATPase pump.
The pharmacodynamic effect of Potassium Phosphate, Dibasic is immediate upon entering the bloodstream (via IV) or within 1-2 hours of oral ingestion. The primary effect is the restoration of serum phosphate levels, which subsequently improves cellular energy metabolism and muscle strength. The duration of effect is dependent on renal function; in healthy individuals, excess phosphate is rapidly excreted, whereas in those with renal impairment, the effect can be prolonged and toxic. There is no evidence of 'tolerance' developing to the mineralizing effects of phosphate, although the body's hormonal response (PTH and FGF23) will shift to maintain homeostasis.
| Parameter | Value |
|---|---|
| Bioavailability | 50% - 70% (Oral) |
| Protein Binding | Negligible |
| Half-life | Variable (Renally dependent) |
| Tmax | 1 - 2 hours (Oral) |
| Metabolism | None (Endogenous ion) |
| Excretion | Renal (>90%) |
Potassium Phosphate, Dibasic is classified as an Electrolyte Replenisher. It is related to other phosphate salts such as Sodium Phosphate (used when potassium must be avoided) and Potassium Acid Phosphate (Monobasic). Within the therapeutic area of mineral metabolism, it is a primary agent for the management of phosphorus deficiency disorders.
Common questions about Jacksons Cell Salts Kali Phos 6x
Potassium Phosphate, Dibasic is primarily used as a source of phosphorus and potassium to treat or prevent hypophosphatemia, a condition where phosphate levels in the blood are dangerously low. It is also used to acidify the urine, which can help prevent the formation of certain kidney stones and manage specific urinary tract infections. In hospital settings, it is a frequent component of intravenous nutrition (TPN) for patients who cannot eat. Additionally, it acts as a buffering agent in many pharmaceutical products to maintain a stable pH level. Your doctor may prescribe it if you have a deficiency caused by malnutrition, chronic illness, or certain metabolic disorders.
The most common side effects associated with Potassium Phosphate, Dibasic are gastrointestinal in nature, including diarrhea, nausea, stomach pain, and bloating. These symptoms occur because the salt draws water into the intestines, which can lead to loose stools. Some patients also report mild headaches or a feeling of thirst after taking the medication. If taken as an injection, some irritation at the site of the infusion may occur. Most of these effects are mild and go away as your body adjusts to the supplement. However, if diarrhea becomes severe or persistent, you should contact your healthcare provider.
It is generally advised to limit or avoid alcohol while taking Potassium Phosphate, Dibasic. Alcohol can interfere with the body's ability to maintain a proper balance of electrolytes and can worsen the gastrointestinal side effects like nausea and diarrhea. Furthermore, chronic alcohol use is a leading cause of phosphate depletion, so continuing to drink may counteract the benefits of the supplement. Alcohol also acts as a diuretic, which can lead to dehydration and put extra strain on the kidneys while they are processing the medication. Always discuss your alcohol consumption habits with your doctor before starting this treatment.
Potassium Phosphate, Dibasic is classified as Pregnancy Category C, meaning its safety has not been fully established through controlled human studies. However, because phosphorus and potassium are essential minerals for both the mother and the developing fetus, it is often used when a clear deficiency exists. Maintaining normal phosphate levels is important for fetal bone development and maternal health. Your doctor will perform a risk-benefit analysis to determine if the supplement is necessary for you. If prescribed, you will likely require frequent blood tests to ensure your levels remain within a safe range for both you and your baby.
The onset of action for Potassium Phosphate, Dibasic depends on the method of administration. If given intravenously, the levels of phosphate and potassium in the blood begin to rise immediately during the infusion. For oral tablets or solutions, it typically takes about 1 to 2 hours for the minerals to be absorbed into the bloodstream. While the blood levels may normalize quickly, it may take several days or even weeks of consistent therapy to replenish the body's total 'stores' of phosphorus, especially in the bones and tissues. Your doctor will use follow-up blood tests to monitor your progress.
You should not stop taking Potassium Phosphate, Dibasic suddenly without consulting your healthcare provider, especially if you are taking it for a chronic condition or a severe deficiency. Abruptly stopping the medication could cause your phosphate levels to drop again, leading to symptoms like muscle weakness, fatigue, and bone pain. If your doctor decides to discontinue the medication, they may choose to taper the dose or monitor your diet to ensure you are getting enough minerals from food. Always follow the specific instructions provided by your medical team to ensure a safe transition.
If you miss a dose of the oral form of this medication, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Never take two doses at once to make up for a missed one, as this can lead to a dangerous spike in potassium or phosphate levels. If you are receiving this medication as an injection in a clinical setting and a dose is delayed, the medical staff will adjust the infusion schedule accordingly. Keeping a consistent schedule helps maintain stable electrolyte levels.
Potassium Phosphate, Dibasic does not typically cause weight gain in the form of increased body fat. However, it can cause the body to retain fluids (edema), which may lead to a sudden increase in weight. This fluid retention is often a sign that the balance between sodium, potassium, and phosphate is shifting. If you notice rapid weight gain, swelling in your ankles or hands, or shortness of breath, you should contact your doctor immediately. These could be signs of a more serious reaction or an underlying issue with how your kidneys are handling the medication.
Potassium Phosphate, Dibasic has several significant interactions with other drugs, particularly those that affect the kidneys or potassium levels. It should not be taken with potassium-sparing diuretics (like Spironolactone) or certain blood pressure medications (like ACE inhibitors) without very close medical supervision, as this increases the risk of dangerous heart rhythms. It also interacts with antacids containing aluminum or magnesium, which can prevent the phosphate from being absorbed. Always provide your doctor with a full list of all medications, over-the-counter drugs, and herbal supplements you are taking to avoid potentially life-threatening interactions.
Yes, Potassium Phosphate, Dibasic is widely available as a generic medication in various forms, including oral powders, tablets, and intravenous solutions. Generic versions are generally as effective as brand-name products and are often more cost-effective for patients. Because it is a basic mineral salt, many different manufacturers produce it. However, because different brands may have different amounts of elemental phosphorus and potassium, you should not switch between brands without checking with your pharmacist or doctor to ensure the dosage remains consistent.
Other drugs with the same active ingredient (Potassium Phosphate, Dibasic)